FDA Determines Regulatory Review Period for VOQUEZNA TRIPLE PAK New Drug Application

Summary

The US Food and Drug Administration (FDA) has determined the regulatory review period for VOQUEZNA TRIPLE PAK, a new drug application (NDA 215152), in response to a patent extension application submitted to the US Patent and Trademark Office (USPTO).